PL2081929T3 - Podstawione związki 3-izobutylo-9,10-dimetoksy-1,3,4,6,7,11b-heksahydro-2H-pirydo[2,1-a]izochinolin-2-olowe i ich wytwarzania - Google Patents
Podstawione związki 3-izobutylo-9,10-dimetoksy-1,3,4,6,7,11b-heksahydro-2H-pirydo[2,1-a]izochinolin-2-olowe i ich wytwarzaniaInfo
- Publication number
- PL2081929T3 PL2081929T3 PL07864160T PL07864160T PL2081929T3 PL 2081929 T3 PL2081929 T3 PL 2081929T3 PL 07864160 T PL07864160 T PL 07864160T PL 07864160 T PL07864160 T PL 07864160T PL 2081929 T3 PL2081929 T3 PL 2081929T3
- Authority
- PL
- Poland
- Prior art keywords
- isoquinolin
- pyrido
- hexahydro
- dimethoxy
- isobutyl
- Prior art date
Links
- WEQLWGNDNRARGE-UHFFFAOYSA-N b-Dihydrotetrabenazine Chemical class C1CN2CC(CC(C)C)C(O)CC2C2=C1C=C(OC)C(OC)=C2 WEQLWGNDNRARGE-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86494406P | 2006-11-08 | 2006-11-08 | |
| EP07864160A EP2081929B1 (en) | 2006-11-08 | 2007-11-08 | Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol compounds and methods relating thereto |
| PCT/US2007/084176 WO2008058261A1 (en) | 2006-11-08 | 2007-11-08 | Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a] isoquinolin-2-ol compounds and methods relating thereto |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2081929T3 true PL2081929T3 (pl) | 2013-06-28 |
Family
ID=39110526
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL07864160T PL2081929T3 (pl) | 2006-11-08 | 2007-11-08 | Podstawione związki 3-izobutylo-9,10-dimetoksy-1,3,4,6,7,11b-heksahydro-2H-pirydo[2,1-a]izochinolin-2-olowe i ich wytwarzania |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US8039627B2 (pl) |
| EP (1) | EP2081929B1 (pl) |
| JP (1) | JP5290185B2 (pl) |
| KR (1) | KR101500766B1 (pl) |
| CN (1) | CN101553487B (pl) |
| AU (1) | AU2007317242B2 (pl) |
| BR (1) | BRPI0718247B1 (pl) |
| CA (1) | CA2668689C (pl) |
| DK (1) | DK2081929T3 (pl) |
| EA (1) | EA018378B1 (pl) |
| ES (1) | ES2402220T3 (pl) |
| IL (1) | IL198250A0 (pl) |
| MX (1) | MX2009004910A (pl) |
| PL (1) | PL2081929T3 (pl) |
| PT (1) | PT2081929E (pl) |
| WO (1) | WO2008058261A1 (pl) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2081929E (pt) | 2006-11-08 | 2013-04-15 | Neurocrine Biosciences Inc | Compostos de 3-isobutil-9,10-dimetoxi- 1,3,4,6,7,11b-hexahidro-2h-pirido[2,1-a]isoquinolin- 2-ol substituídos e métodos com estes relacionados |
| NO3061760T3 (pl) | 2008-09-18 | 2018-04-07 | ||
| WO2011153157A2 (en) * | 2010-06-01 | 2011-12-08 | Auspex Pharmaceutical, Inc. | Benzoquinolone inhibitors of vmat2 |
| WO2012000308A1 (zh) * | 2010-06-29 | 2012-01-05 | 中国药科大学 | 丁苯那嗪的拆分方法 |
| US8351329B2 (en) * | 2010-09-14 | 2013-01-08 | Cisco Technology, Inc. | Universal load-balancing tunnel encapsulation |
| CN102285984B (zh) * | 2010-11-25 | 2012-10-10 | 江苏威凯尔医药科技有限公司 | (2R,3R,11bR)-二氢丁苯那嗪及相关化合物的制备方法 |
| WO2012081031A1 (en) * | 2010-12-15 | 2012-06-21 | Enaltec Labs Pvt. Ltd. | Process for preparing tetrabenazine |
| CA2883641C (en) | 2012-09-18 | 2021-09-14 | Auspex Pharmaceuticals, Inc. | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| US9550780B2 (en) | 2012-09-18 | 2017-01-24 | Auspex Pharmaceuticals, Inc. | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| HK1219095A1 (zh) * | 2013-01-31 | 2017-03-24 | Auspex Pharmaceuticals, Inc. | Vmat2的benzoquinolone抑制剂 |
| US20160207917A1 (en) * | 2013-09-27 | 2016-07-21 | Auspex Pharmaceuticals, Inc. | Benzoquinolone inhibitors of vmat2 |
| BR112016012747B1 (pt) | 2013-12-03 | 2022-07-12 | Auspex Pharmaceuticals, Inc | Processo de preparação de uma mistura racêmica de (rr,ss)-d6-tetrabenazina |
| MX2016009817A (es) * | 2014-01-27 | 2017-02-28 | Auspex Pharmaceuticals Inc | Inhibidores de benzoquinolina del transportador vesicular de monoaminas 2. |
| US10166183B2 (en) | 2014-02-07 | 2019-01-01 | Auspex Pharmaceuticals, Inc. | Pharmaceutical formulations |
| CN106061506A (zh) | 2014-02-07 | 2016-10-26 | 纽罗克里生物科学有限公司 | 包含抗精神病药物和vmat2抑制剂的药物组合物及其用途 |
| RS59559B1 (sr) | 2014-02-13 | 2019-12-31 | Incyte Corp | Ciklopropilamini kao lsd1 inhibitori |
| FI3936130T3 (fi) * | 2014-05-06 | 2024-04-23 | Neurocrine Biosciences Inc | Valbenatsiinin annostusohjelma hyperkineettisten liikehäiriöiden hoitoon |
| EP3253752B1 (en) * | 2015-02-06 | 2023-08-16 | Neurocrine Biosciences, Inc. | [9,10-dimethoxy-3-(2-methylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto |
| CN114767672A (zh) | 2015-03-06 | 2022-07-22 | 奥斯拜客斯制药有限公司 | 氘代丁苯那嗪或包含氘代丁苯那嗪的组合物 |
| TWI714567B (zh) | 2015-04-03 | 2021-01-01 | 美商英塞特公司 | 作為lsd1抑制劑之雜環化合物 |
| AU2016282790B9 (en) * | 2015-06-23 | 2020-01-30 | Neurocrine Biosciences, Inc. | VMAT2 inhibitors for treating neurological diseases or disorders |
| HUE070538T2 (hu) | 2015-08-12 | 2025-06-28 | Incyte Holdings Corp | Egy LSD1 inhibitor sói |
| EP3359148A1 (en) | 2015-10-09 | 2018-08-15 | Teva Pharmaceuticals International GmbH | Combination of deuterated levodopa with carbidopa and opicapone for the treatment of parkinson`s disease |
| MY193767A (en) * | 2015-10-30 | 2022-10-27 | Neurocrine Biosciences Inc | Valbenazine salts and polymorphs thereof |
| US10160757B2 (en) * | 2015-12-23 | 2018-12-25 | Neuroscrine Biosciences, Inc. | Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) |
| US10479787B2 (en) | 2016-04-22 | 2019-11-19 | Lupin Limited | Process for preparation of tetrabenazine and deutetrabenazine |
| WO2018001335A1 (zh) | 2016-06-29 | 2018-01-04 | 苏州科睿思制药有限公司 | Nbi-98854的晶型及其制备方法和用途 |
| WO2018067945A1 (en) * | 2016-10-06 | 2018-04-12 | Assia Chemical Industries Ltd. | Solid state forms of valbenazine |
| EP4400171A3 (en) | 2016-12-02 | 2024-09-11 | Neurocrine Biosciences, Inc. | Use of valbenazine for treating schizophrenia or schizoaffective disorder |
| US10703750B2 (en) | 2017-01-10 | 2020-07-07 | Sandoz Ag | Crystalline valbenazine free base |
| MX394415B (es) * | 2017-01-27 | 2025-03-24 | Neurocrine Biosciences Inc | Metodos para la administracion de ciertos inhibidores de proteina transportadora transportador de monoamina vesicular-2 (vmat2). |
| CA3054238A1 (en) | 2017-02-27 | 2018-08-30 | Sandoz Ag | Crystalline forms of valbenazine salts |
| WO2018164996A1 (en) | 2017-03-06 | 2018-09-13 | Neurocrine Biosciences, Inc. | Dosing regimen for valbenazine |
| WO2018170214A1 (en) | 2017-03-15 | 2018-09-20 | Zhang Chengzi | Analogs of deutetrabenazine, their preparation and use |
| GB201705304D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705302D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| WO2018178243A2 (en) * | 2017-04-01 | 2018-10-04 | Adeptio Pharmaceuticals Limited | Pharmaceutical compositions |
| GB201705306D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705303D0 (en) * | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705305D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| JOP20190239A1 (ar) | 2017-04-19 | 2019-10-09 | Neurocrine Biosciences Inc | مركبات مثبطة لـ vmat2 وتركيبات منها |
| WO2018200605A1 (en) | 2017-04-26 | 2018-11-01 | Neurocrine Biosciences, Inc. | Use of valbenazine for treating levodopa-induced dyskinesia |
| IL309802A (en) | 2017-09-21 | 2024-02-01 | Neurocrine Biosciences Inc | High dose valbenazine formulation and related preparations, methods and kits |
| US20200230127A1 (en) * | 2017-10-10 | 2020-07-23 | Neurocrine Biosciences, Inc. | Methods for the Administration of Certain VMAT2 Inhibitors |
| KR20250070134A (ko) | 2017-10-10 | 2025-05-20 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
| CN111343985A (zh) * | 2017-11-08 | 2020-06-26 | 逸达生物科技股份有限公司 | 二氢丁苯那嗪的酯 |
| US11384077B2 (en) | 2017-11-22 | 2022-07-12 | Assia Chemical Industries Ltd. | Solid state form of Valbenazine |
| US11339158B2 (en) | 2017-12-26 | 2022-05-24 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Crystalline form of valbenazine ditosylate, processes for preparation thereof and use thereof |
| CN110092785A (zh) * | 2018-01-31 | 2019-08-06 | 广东东阳光药业有限公司 | 一种丁苯那嗪的动态拆分方法 |
| GB201808464D0 (en) | 2018-05-23 | 2018-07-11 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compounds for use in treating huntington's disease |
| KR20210021006A (ko) | 2018-06-14 | 2021-02-24 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | Vmat2 억제제 화합물, 조성물 및 그와 관련된 방법 |
| KR20210044817A (ko) | 2018-08-15 | 2021-04-23 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
| WO2020047198A1 (en) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Salts of an lsd1 inhibitor and processes for preparing the same |
| EP3860599B1 (en) | 2018-10-04 | 2024-05-15 | Adeptio Pharmaceuticals Limited | (+)-alpha-dihydrotetrabenazine dosage regimen for treating movement disorders |
| CA3065236A1 (en) | 2018-12-27 | 2020-06-27 | Apotex Inc. | Novel crystalline form of valbenazine dibesylate |
| WO2020213014A1 (en) | 2019-04-19 | 2020-10-22 | Mylan Laboratories Limited | An improved process for the preparation of valbenazine and its salts |
| US10689380B1 (en) | 2019-07-30 | 2020-06-23 | Farmhispania S.A. | Crystalline forms of valbenazine ditosylate |
| KR20220035204A (ko) * | 2019-08-12 | 2022-03-21 | 산동 루예 파마슈티칼 컴파니 리미티드 | Vmat2 억제제 및 이의 제조 방법 및 용도 |
| US10940141B1 (en) | 2019-08-23 | 2021-03-09 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
| CN114423755A (zh) | 2019-09-13 | 2022-04-29 | 纽罗克里生物科学有限公司 | 用于合成缬苯那嗪的方法 |
| CN110698397A (zh) * | 2019-10-28 | 2020-01-17 | 南京红杉生物科技有限公司 | 丁苯那嗪中间体及其合成方法、应用和合成用中间产物 |
| AR125188A1 (es) | 2021-03-22 | 2023-06-21 | Neurocrine Biosciences Inc | Inhibidores del vmat2 y métodos de uso |
| US20240239791A1 (en) | 2021-04-26 | 2024-07-18 | Neurocrine Biosciences, Inc. | Processes for the synthesis of valbenazine |
| MX2023014977A (es) | 2021-06-30 | 2024-02-09 | Neurocrine Biosciences Inc | Valbenazina para usarse en el tratamiento de discinesia debido a paralisis cerebral. |
| IL309172A (en) | 2021-06-30 | 2024-02-01 | Neurocrine Biosciences Inc | Vulbanazine for use in the additional treatment of schizophrenia |
| EP4489754A1 (en) | 2022-03-07 | 2025-01-15 | Neurocrine Biosciences, Inc. | Valbenazine, a vmat2 inhibitor, as a free base a tosylate or ditosylate salt, for use in the treatment of chorea associated with huntington's disease |
| CA3267926A1 (en) | 2022-09-21 | 2024-03-28 | Neurocrine Biosciences, Inc. | HEXAHYDRO-2H-PYRIDO[2,1-A]ISOQUINOLINE VMAT2 INHIBITORS AND METHODS OF USE |
| WO2025038959A1 (en) | 2023-08-17 | 2025-02-20 | Neurocrine Biosciences, Inc. | Methods for the administration of certain vmat2 inhibitors |
| TW202521119A (zh) | 2023-08-17 | 2025-06-01 | 美商紐羅克里生物科學有限公司 | 用於投與特定vmat2抑制劑之方法 |
| WO2025096823A1 (en) | 2023-11-01 | 2025-05-08 | Neurocrine Biosciences, Inc. | Improvement, maintenance or reduction of decline of motor function associated with huntington disease using valbenazine |
| WO2025188830A1 (en) | 2024-03-06 | 2025-09-12 | Neurocrine Biosciences, Inc. | Methods for the administration of certain vmat2 inhibitors |
| WO2025199234A1 (en) | 2024-03-20 | 2025-09-25 | Neurocrine Biosciences, Inc. | Vmat2 inhibitors and methods of use |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3209005A (en) * | 1965-09-28 | Hexahydro-llbh-benzo[a] quinolizines and processes therefor | ||
| US2843591A (en) * | 1958-07-15 | Method for preparing same | ||
| US2852518A (en) * | 1957-05-23 | 1958-09-16 | Parke Davis & Co | Di-substituted quinoline compounds |
| WO1991016920A1 (en) | 1990-05-07 | 1991-11-14 | Vical, Inc. | Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs |
| US6610841B1 (en) | 1997-12-18 | 2003-08-26 | Gilead Sciences, Inc. | Nucleotide-based prodrugs |
| US7045543B2 (en) * | 2001-11-05 | 2006-05-16 | Enzrel Inc. | Covalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites |
| GB2410947B (en) | 2004-02-11 | 2008-09-17 | Cambridge Lab Ltd | Pharmaceutical compounds |
| WO2006053067A2 (en) | 2004-11-09 | 2006-05-18 | Prestwick Pharmaceuticals, Inc. | Combination of amantadine and a tetrabenazine compound for treating hyperkinetic disorders |
| US20090202428A1 (en) | 2005-06-29 | 2009-08-13 | Paul Harris | Use of Dtbz for Imaging Endocrine Pancreas and Beta Cell Mass In Type 1 Diabetes |
| GB0514501D0 (en) | 2005-07-14 | 2005-08-24 | Cambridge Lab Ireland Ltd | Pharmaceutical compounds |
| GB0516168D0 (en) | 2005-08-05 | 2005-09-14 | Cambridge Lab Ireland Ltd | Pharmaceutical compounds |
| US20110257220A1 (en) | 2005-08-06 | 2011-10-20 | Cambridge Laboratories (Ireland) Limited | 3,11 b-cis-Dihydrotetrabenazine for the Treatment of Schizophrenia and Other Psychoses |
| PT2081929E (pt) | 2006-11-08 | 2013-04-15 | Neurocrine Biosciences Inc | Compostos de 3-isobutil-9,10-dimetoxi- 1,3,4,6,7,11b-hexahidro-2h-pirido[2,1-a]isoquinolin- 2-ol substituídos e métodos com estes relacionados |
-
2007
- 2007-11-08 PT PT78641602T patent/PT2081929E/pt unknown
- 2007-11-08 EA EA200970461A patent/EA018378B1/ru unknown
- 2007-11-08 MX MX2009004910A patent/MX2009004910A/es active IP Right Grant
- 2007-11-08 KR KR1020097011731A patent/KR101500766B1/ko active Active
- 2007-11-08 BR BRPI0718247-3A patent/BRPI0718247B1/pt active IP Right Grant
- 2007-11-08 JP JP2009536493A patent/JP5290185B2/ja active Active
- 2007-11-08 AU AU2007317242A patent/AU2007317242B2/en active Active
- 2007-11-08 WO PCT/US2007/084176 patent/WO2008058261A1/en not_active Ceased
- 2007-11-08 EP EP07864160A patent/EP2081929B1/en active Active
- 2007-11-08 US US11/937,445 patent/US8039627B2/en active Active
- 2007-11-08 ES ES07864160T patent/ES2402220T3/es active Active
- 2007-11-08 PL PL07864160T patent/PL2081929T3/pl unknown
- 2007-11-08 CA CA2668689A patent/CA2668689C/en active Active
- 2007-11-08 CN CN2007800395790A patent/CN101553487B/zh active Active
- 2007-11-08 DK DK07864160.2T patent/DK2081929T3/da active
-
2009
- 2009-04-21 IL IL198250A patent/IL198250A0/en active IP Right Grant
-
2011
- 2011-09-20 US US13/237,709 patent/US8357697B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US8357697B2 (en) | 2013-01-22 |
| KR20090079257A (ko) | 2009-07-21 |
| ES2402220T3 (es) | 2013-04-29 |
| US20120077839A1 (en) | 2012-03-29 |
| WO2008058261A1 (en) | 2008-05-15 |
| IL198250A0 (en) | 2009-12-24 |
| BRPI0718247B1 (pt) | 2021-09-21 |
| PT2081929E (pt) | 2013-04-15 |
| KR101500766B9 (ko) | 2024-09-25 |
| EP2081929B1 (en) | 2013-01-09 |
| BRPI0718247A2 (pt) | 2014-01-07 |
| AU2007317242A1 (en) | 2008-05-15 |
| CN101553487A (zh) | 2009-10-07 |
| AU2007317242B2 (en) | 2013-08-01 |
| JP2010509366A (ja) | 2010-03-25 |
| MX2009004910A (es) | 2009-07-24 |
| ES2402220T8 (es) | 2021-12-23 |
| US8039627B2 (en) | 2011-10-18 |
| EP2081929A1 (en) | 2009-07-29 |
| EA018378B1 (ru) | 2013-07-30 |
| KR101500766B1 (ko) | 2015-03-16 |
| CA2668689A1 (en) | 2008-05-15 |
| DK2081929T3 (da) | 2013-04-15 |
| US20080167337A1 (en) | 2008-07-10 |
| CA2668689C (en) | 2015-12-29 |
| JP5290185B2 (ja) | 2013-09-18 |
| CN101553487B (zh) | 2012-06-13 |
| EA200970461A1 (ru) | 2009-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2081929T3 (pl) | Podstawione związki 3-izobutylo-9,10-dimetoksy-1,3,4,6,7,11b-heksahydro-2H-pirydo[2,1-a]izochinolin-2-olowe i ich wytwarzania | |
| GB0606655D0 (en) | Showerpod 1 | |
| GB0618761D0 (en) | Derivatives 2 | |
| GB0613922D0 (en) | E S V Roadsafe 1000 | |
| GB0617317D0 (en) | Iifa 2007 Yorkshire | |
| GB0604494D0 (en) | Corcost 5 | |
| GB0603759D0 (en) | MoveClick 12 | |
| GB0602974D0 (en) | Moveclick 9 | |
| GB0601236D0 (en) | MoveClick 7 | |
| GB0703784D0 (en) | 74 | |
| GB0619930D0 (en) | Corcost 0031 | |
| GB0604313D0 (en) | MoveClick 14 | |
| GB0604926D0 (en) | MoveClick 15 | |
| GB0603050D0 (en) | Moveclick 10 | |
| GB0604112D0 (en) | Moveclick 13 | |
| GB0619890D0 (en) | Corcost 0020 | |
| GB0615357D0 (en) | Corcost 2006 | |
| GB0615330D0 (en) | Corcost 2006 | |
| GB0615059D0 (en) | Corcost 506 | |
| GB0615058D0 (en) | Corcost 406 | |
| GB0615057D0 (en) | Corcost 306 | |
| GB0615056D0 (en) | Corcost 106 | |
| GB0615051D0 (en) | Corcost 1306 | |
| GB0615050D0 (en) | Corcost 706 | |
| GB0612310D0 (en) | Corcost 1506 |